NASDAQ, ENDP - Endo Int'l Plc
We are a specialty pharmaceutical company with market leadership in pain
management. We are engaged in the research, development, sale and marketing of
branded and generic prescription pharmaceuticals used primarily to treat and
manage pain.
We have a portfolio of branded products that includes established brand names
such as Lidoderm?, Opana? ER and Opana?, Percocet? and Frova?. Branded products
comprised approximately 92% of our net sales in 2007, with 65% of our net sales
coming from Lidoderm?. Our non-branded generic portfolio, which accounted for 8%
of net sales in 2007, currently consists of products primarily focused in pain
management. We focus selectively on generics that have one or more barriers to
market entry, such as complex formulation, regulatory or legal challenges or
difficulty in raw material sourcing. ...
Read SEC Filing on NASDAQ.com »